CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I and a Randomized Phase II Study of Maximal Angiogenic Blockade in Advanced Renal Carcinoma: Bevacizumab (NSC-704865) With or Without MEDI-522 (NSC-719850)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00684996
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:42.665814+00:00
Published At: 2014-01-14T00:00:00+00:00
Record Updated At: 2014-05-15
Results Posted At: 2014-01-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Renal Cell Cancer", "Renal Cell Carcinoma", "Stage III Renal Cell Cancer", "Stage IV Renal Cell Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2014-05-15"
protocolSection.identificationModule.nctId: "NCT00684996"
protocolSection.identificationModule.officialTitle: "A Phase I and a Randomized Phase II Study of Maximal Angiogenic Blockade in Advanced Renal Carcinoma: Bevacizumab (NSC-704865) With or Without MEDI-522 (NSC-719850)"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2014-01-14"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.